| NCT ID | NCT05178277 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Thomayer University Hospital |
| Condition | Alpha-1-antitrypsin Deficiency |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2018-01-01 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2018-01-01 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.
Eligibility Criteria
Inclusion Criteria: * Patients with alpha-1-antitrypsin deficiency Exclusion Criteria: * Patient disagreement with inclusion in the study
Contact & Investigator
Jan MD Chlumsky, PhD
PRINCIPAL INVESTIGATOR
Thomayer University Hospital
Frequently Asked Questions
Who can join the NCT05178277 clinical trial?
This trial is open to participants of all sexes, studying Alpha-1-antitrypsin Deficiency. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05178277 currently recruiting?
Yes, NCT05178277 is actively recruiting participants. Contact the research team at kusalova@biostatistika.cz for enrollment information.
Where is the NCT05178277 trial being conducted?
This trial is being conducted at Prague, Czechia.
Who is sponsoring the NCT05178277 clinical trial?
NCT05178277 is sponsored by Thomayer University Hospital. The principal investigator is Jan MD Chlumsky, PhD at Thomayer University Hospital. The trial plans to enroll 300 participants.